A China-based private equity firm affiliated with a global investment group has raised multiple funds to date and invests across multiple sectors, including healthcare. The firm is a full-spectrum investor, participating from Series A through pre-IPO and PIPE, and may also consider buyouts and add-on acquisitions for its portfolio. Typical investments range from $5-50M, with the capacity to commit up to $100M per company. While the firm is primarily focused on opportunities in China, it also invests in companies from the US and Europe that present a strong China angle.
The firm invests opportunistically in the healthcare sector on a case-by-case basis. Areas of interest include biopharma, medical devices and equipment, diagnostics, healthcare IT, and R&D services with significant market potential. The firm is stage-agnostic and will consider products ranging from pre-clinical through market-approved.
The firm invests in both private and public companies, targeting Chinese businesses as well as US- and Europe-based companies with strategic ties to the China market.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment